• H. Dunbar Hoskins Jr., MDThe H. Dunbar Hoskins Jr., M.D. Center for Quality Eye Care was established as a quality of care and health policy research center that advances the accessibility to and appropriateness of eye care services. The work of the Hoskins Center will help ensure that patients continue to receive high quality, evidence-based eye care within a tightening economic environment that demands increased value for services provided.

  • from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Diabetic Retinopathy.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Age-Related Macular Degeneration.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Retinal Vein Occlusions.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Idiopathic Macular Hole.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Retinal and Ophthalmic Artery Occlusions.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Idiopathic Epiretinal Membrane and Vitreomacular Traction.
    Preferred Practice Pattern Guideline
    from AAO PPP Retina/Vitreous Committee, Hoskins Center for Quality Eye Care
    Updated evidence-based Retina/Vitreous Preferred Practice Pattern® (PPP), addressing Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration.
    Preferred Practice Pattern Guideline
    from AAO PPP Panels, Hoskins Center for Quality Eye Care
    Recommendations distilled from the various Preferred Practice Pattern® (PPP) Guidelines titles.
    Summary Benchmark Translations
    from AAO PPP Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Recommendations distilled from the PPPs for AMD; diabetic retinopathy; idiopathic epiretinal membrane and vitreomacular traction; idiopathic macular hole; posterior vitreous detachment, retinal breaks, and lattice degeneration; retinal and ophthalmic artery occlusions; and r…
    Summary Benchmark Translations
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Strong evidence indicates intravitreal pharmacotherapy with anti-VEGF agents is a safe and effective therapy for ME secondary to BRVO. Intravitreal corticosteroids are associated with greater side effects and VA is less optimal with laser photocoagulation treatments.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence suggests that combination intravitreal foscarnet and systemic therapy may be more effective than systemic therapy in the treatment of acute retinal necrosis (ARN). While PCR testing reliably confirms ARN cases, antiviral treatment must not be delayed.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review pertaining to the efficacy and safety of therapies for the treatment of macular edema associated with central retinal vein occlusion (CRVO)
    Ophthalmic Technology Assessment
    from OMIC and AAO Quality of Care Secretariat, Hoskins Center for Quality Eye Care
    Provides information and resources from the Ophthalmic Mutual Insurance Company (OMIC) and Academy about bevacizumab intravitreal injections to minimize risks of infection from the compounding process.
    Clinical Statement
    from AAO Task Force on Genetic Testing
    The Academy's Task Force report on genetic testing that provides guidance on the underlying principles and approaches of genetic testing.
    Clinical Statement
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review of the literature for the outcomes and safety of interventions for toxoplasma retinochoroiditis
    Ophthalmic Technology Assessment
    from AAP, AAPOS and AAO Hoskins Center for Quality Eye Care
    The American Academy of Pediatrics (AAP), American Association for Pediatric Ophthalmology and Strabismus (AAPOS), and Academy outline principles of a screening program to detect ROP in infants at risk; includes suggested guidelines for the United States.
    Clinical Statement
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review of the literature supporting the treatment of diabetic macular edema with anti-VEGF pharmacotherapy
    Ophthalmic Technology Assessment
    from Global Diabetic Retinopathy Project Task Force and Invitational Workshop, AAO Hoskins Center for Quality Eye Care
    International disease severity scale based on the early treatment diabetic retinopathy study (ETDRS) classification of diabetic retinopathy, clinical trials, and epidemiologic studies.
    Clinical Statement
    from AAO Quality of Care Secretariat, Hoskins Center for Quality Eye Care
    The Eye Examination Report form is designed to improve communication regarding a diabetic patient's retinopathy status. The completed form should be shared between the ophthalmologist and a primary care physician, or referring physician.
    Clinical Statement
    from U.K. National Health Service, National Institute for Health and Care Excellence
    A clinical guideline covering the care and treatment of people with type 2 diabetes in the National Health Service in England and Wales. Describes the detection and management process, and referral to a specialist for diabetic eye disease.
    Clinical Statement